DK3397968T3 - Inhibitorer af urea-baseret prostata-specifikt membranantigen (PSMA) til billeddannelse og terapi - Google Patents
Inhibitorer af urea-baseret prostata-specifikt membranantigen (PSMA) til billeddannelse og terapi Download PDFInfo
- Publication number
- DK3397968T3 DK3397968T3 DK16882430.8T DK16882430T DK3397968T3 DK 3397968 T3 DK3397968 T3 DK 3397968T3 DK 16882430 T DK16882430 T DK 16882430T DK 3397968 T3 DK3397968 T3 DK 3397968T3
- Authority
- DK
- Denmark
- Prior art keywords
- psma
- urea
- inhibitors
- therapy
- imaging
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- 238000003384 imaging method Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Nuclear Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273786P | 2015-12-31 | 2015-12-31 | |
| US15/385,490 US10688200B2 (en) | 2015-12-31 | 2016-12-20 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| PCT/US2016/068327 WO2017116994A1 (en) | 2015-12-31 | 2016-12-22 | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3397968T3 true DK3397968T3 (da) | 2021-11-01 |
Family
ID=59225798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16882430.8T DK3397968T3 (da) | 2015-12-31 | 2016-12-22 | Inhibitorer af urea-baseret prostata-specifikt membranantigen (PSMA) til billeddannelse og terapi |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10688200B2 (da) |
| EP (1) | EP3397968B1 (da) |
| JP (1) | JP6850027B2 (da) |
| KR (1) | KR102766172B1 (da) |
| CN (1) | CN108541302B (da) |
| AU (2) | AU2016380151A1 (da) |
| CA (1) | CA3010295C (da) |
| DK (1) | DK3397968T3 (da) |
| EA (1) | EA201891544A1 (da) |
| IL (1) | IL260342A (da) |
| MX (1) | MX2018008168A (da) |
| SG (1) | SG11201805380YA (da) |
| WO (1) | WO2017116994A1 (da) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| HUE066137T2 (hu) | 2013-10-18 | 2024-07-28 | Novartis Ag | A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére |
| JP6464166B2 (ja) | 2013-11-14 | 2019-02-06 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 陽電子放出断層撮影用の化合物 |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| SI3925952T1 (sl) * | 2016-03-22 | 2024-03-29 | The Johns Hopkins University | Za prostato specifična, na membranski antigen usmerjena visoko afinitetna sredstva za endoradioterapijo raka prostate |
| EP3618867A4 (en) | 2017-05-02 | 2021-01-20 | Cornell University | METHODS AND REAGENTS FOR TUMOR TARGETING WITH IMPROVED EFFICIENCY AND REDUCED TOXICITY |
| CN118146170A (zh) * | 2017-05-30 | 2024-06-07 | 约翰霍普金斯大学 | 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂 |
| DK3723815T3 (da) | 2017-12-11 | 2022-07-11 | Univ Muenchen Tech | PSMA ligander til billeddannelse og endoradioterapi |
| US20190184040A1 (en) * | 2017-12-15 | 2019-06-20 | Wisconsin Alumni Research Foundation | Targeted Macrocyclic Agents for Dual Modality PET and MRI Imaging of Cancer |
| MX380340B (es) * | 2018-03-14 | 2025-03-11 | Instituto Nac De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofarmaco terapeutico dirigido al antigeno prostatico especifico de membrana. |
| CA3097381A1 (en) | 2018-04-17 | 2019-10-24 | Endocyte, Inc. | Methods of treating cancer |
| EP3636635A1 (en) | 2018-10-11 | 2020-04-15 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Imaging agents |
| CN109438517B (zh) * | 2018-12-27 | 2021-01-08 | 北京久杰净化工程技术有限公司 | 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法 |
| WO2020210909A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
| CN114364405B (zh) * | 2019-04-26 | 2024-07-16 | 五一一制药股份有限公司 | 作为诊断剂和放射性核素治疗剂的前列腺特异性膜抗原(psma)抑制剂 |
| CN120097930A (zh) | 2019-05-20 | 2025-06-06 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CA3144094A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| US20230098279A1 (en) * | 2020-02-18 | 2023-03-30 | Endocyte, Inc. | Method of treating psma-expressing cancers |
| CA3194592A1 (en) * | 2020-10-01 | 2022-04-07 | Neil H. Bander | Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands |
| CN112358422B (zh) * | 2020-10-16 | 2023-06-23 | 中国辐射防护研究院 | 一种新型螯合剂nbed的制备方法 |
| EP4029523A1 (en) * | 2021-01-19 | 2022-07-20 | Orano Med | Psma-targeting conjugate and uses thereof |
| US20240158420A1 (en) * | 2021-03-17 | 2024-05-16 | Five Eleven Pharma, Inc | [18f]a1f labeled psma targeting molecular probe and preparation method therefor |
| CN113372285B (zh) * | 2021-05-28 | 2024-06-18 | 西南医科大学附属医院 | 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用 |
| CN114316075B (zh) * | 2021-11-12 | 2023-03-14 | 青岛农业大学 | 一种聚集诱导发光高分子及其制备方法和应用 |
| CN114436905A (zh) * | 2022-01-24 | 2022-05-06 | 攀枝花学院 | 3-醛基-4-羟基苯乙酸甲酯的纯化方法 |
| WO2023143612A1 (zh) * | 2022-01-30 | 2023-08-03 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
| CN114874122A (zh) * | 2022-05-31 | 2022-08-09 | 南京航空航天大学 | 一种新的小分子抑制剂及其制备方法和应用 |
| WO2024021556A1 (zh) * | 2023-02-02 | 2024-02-01 | 北京师范大学 | 一种靶向前列腺特异性膜抗原的放射性金属配合物及其标记配体 |
| WO2023231452A1 (zh) * | 2023-02-14 | 2023-12-07 | 北京师范大学 | 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 |
| CN118496299A (zh) * | 2023-02-16 | 2024-08-16 | 无锡诺宇医药科技有限公司 | Psma靶向放射性诊疗一体化药物及其合成和应用 |
| CN117924253A (zh) * | 2023-08-17 | 2024-04-26 | 厦门大学 | 谷氨酸尿素类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物 |
| CN119301141A (zh) * | 2024-01-15 | 2025-01-10 | 中国医学科学院北京协和医院 | 双靶向肿瘤细胞的化合物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060523A1 (en) | 2002-01-10 | 2003-07-24 | Johns Hopkins University | Imaging agents and methods of imaging naaladase of psma |
| US8338565B2 (en) | 2008-08-20 | 2012-12-25 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| WO2012174136A1 (en) * | 2011-06-15 | 2012-12-20 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
| EP2739316B1 (en) | 2011-08-05 | 2019-04-10 | Molecular Insight Pharmaceuticals, Inc. | Radiolabeled prostate specific membrane antigen inhibitors |
| US9371360B2 (en) * | 2011-11-30 | 2016-06-21 | The Johns Hopkins University | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PSMA) and uses thereof |
| KR102354613B1 (ko) * | 2012-11-15 | 2022-01-21 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
| JP6468602B2 (ja) * | 2013-01-14 | 2019-02-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | トリアジン系放射性医薬品及び放射線造影剤 |
| US10406246B2 (en) | 2013-10-17 | 2019-09-10 | Deutsches Kresbsforschungszentrum | Double-labeled probe for molecular imaging and use thereof |
| HUE066137T2 (hu) * | 2013-10-18 | 2024-07-28 | Novartis Ag | A prosztata-specifikus membrán antigén (PSMA) jelzett inhibitorai, alkalmazásuk képalkotásban és gyógyszerkészítmények prosztatarák kezelésére |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| JP6464166B2 (ja) * | 2013-11-14 | 2019-02-06 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | 陽電子放出断層撮影用の化合物 |
| EP3140282B1 (en) * | 2014-05-06 | 2019-07-10 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2016
- 2016-12-20 US US15/385,490 patent/US10688200B2/en active Active - Reinstated
- 2016-12-22 CN CN201680079844.7A patent/CN108541302B/zh active Active
- 2016-12-22 AU AU2016380151A patent/AU2016380151A1/en not_active Abandoned
- 2016-12-22 SG SG11201805380YA patent/SG11201805380YA/en unknown
- 2016-12-22 WO PCT/US2016/068327 patent/WO2017116994A1/en not_active Ceased
- 2016-12-22 EP EP16882430.8A patent/EP3397968B1/en active Active
- 2016-12-22 MX MX2018008168A patent/MX2018008168A/es unknown
- 2016-12-22 DK DK16882430.8T patent/DK3397968T3/da active
- 2016-12-22 JP JP2018534552A patent/JP6850027B2/ja active Active
- 2016-12-22 EA EA201891544A patent/EA201891544A1/ru unknown
- 2016-12-22 CA CA3010295A patent/CA3010295C/en active Active
- 2016-12-22 KR KR1020187021593A patent/KR102766172B1/ko active Active
-
2018
- 2018-06-28 IL IL260342A patent/IL260342A/en unknown
-
2023
- 2023-06-13 AU AU2023203682A patent/AU2023203682B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10688200B2 (en) | 2020-06-23 |
| JP2019508374A (ja) | 2019-03-28 |
| SG11201805380YA (en) | 2018-07-30 |
| WO2017116994A1 (en) | 2017-07-06 |
| CN108541302A (zh) | 2018-09-14 |
| EA201891544A1 (ru) | 2018-11-30 |
| CN108541302B (zh) | 2023-02-14 |
| HK1255215A1 (zh) | 2019-08-09 |
| MX2018008168A (es) | 2019-02-20 |
| EP3397968A1 (en) | 2018-11-07 |
| KR102766172B1 (ko) | 2025-02-12 |
| CA3010295C (en) | 2023-09-26 |
| CA3010295A1 (en) | 2017-07-06 |
| KR20180098373A (ko) | 2018-09-03 |
| IL260342A (en) | 2018-08-30 |
| EP3397968A4 (en) | 2019-11-27 |
| US20170189568A1 (en) | 2017-07-06 |
| JP6850027B2 (ja) | 2021-03-31 |
| EP3397968B1 (en) | 2021-09-29 |
| AU2023203682A1 (en) | 2023-07-06 |
| AU2023203682B2 (en) | 2025-07-24 |
| AU2016380151A1 (en) | 2018-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3397968T3 (da) | Inhibitorer af urea-baseret prostata-specifikt membranantigen (PSMA) til billeddannelse og terapi | |
| DK3280441T3 (da) | Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK4095130T3 (da) | Mærkede hæmmere af prostataspecifikt membranantigen (psma), deres anvendelse som billeddannelsesmidler og farmaceutiske midler til behandling af prostatacancer | |
| DK3353210T3 (da) | Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse | |
| DK3534899T3 (da) | Forbindelser og fremgangsmåder til modulering af interleukin-2-inducerbar t-cellekinase | |
| DK3267884T3 (da) | Systemer, apparater og fremgangsmåder til måling af føtal aktivitet | |
| DK3295951T3 (da) | Anti-pvrig-antistoffer og fremgangsmåder for anvendelse | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3265947T3 (da) | Fremgangsmåde og system til kryptering | |
| DK3303394T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3486604T3 (da) | Indretning til intraoral tredimensionel måling, fremgangsmåde til intraoral tredimensionel måling og fremgangsmåde til visning af resultat af intraoral tredimensionel måling | |
| DK3356385T3 (da) | 18f-taggede inhibitorer af prostataspecifik membranantigen (psma) og deres anvendelse til billededannelsesforbindelser til prostatakræft | |
| DK3359052T3 (da) | Indretning til opsamling af væv og fremgangsmåde til anvendelse | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3129912T3 (da) | Fremgangsmåde og system til sikring af data | |
| DK3260813T3 (da) | System og fremgangsmåde til afstandsbedømmelse | |
| DK3264886T3 (da) | System og fremgangsmåde til observation af pattegrisefødsel | |
| DK3826667T3 (da) | Claudin6-antistoffer og fremgangsmåder til behandling af kræft | |
| DK3116911T3 (da) | Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse | |
| DK3294143T3 (da) | Systemer og metoder til billeddannelse af biologiske vævsstrukturer | |
| DK3514151T3 (da) | Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf | |
| DK3377653T3 (da) | Fremgangsmåder til opnåelse og korrektion af biologisk sekvensinformation | |
| DK3390442T5 (da) | Anti-C5 antistoffer og fremgangsmåde til anvendelse deraf | |
| DK3102184T3 (da) | Stabile formuleringer af peptider og fremgangsmåder til fremstilling | |
| DK3368578T3 (da) | Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf |